Patent ID: 8741949
Filing Date: 2014-06-03
Classification: A61K,A61P

Abstract:
1. A method of treating disorders caused by delipidation of neural tissue, wherein the disorders are primary disorders which affect the brain directly and selectively and which are selected from the group consisting of multiple sclerosis, mental and/or behavioural disorder which are caused by psychoactive substance use, schizoid personality disorder, depression, depressive episode, recurrent depressive disorder, persistent mood disorder, mental retardation and impairment of memory and which are not secondary disorders wherein the brain is attacked as one of multiple organs of the body by administering to a patient a Carnitin-Palmitoyl-Transferase-1 (CPT-1) inhibitor in a pharmacologically effective amount, whereby the CPT-1 inhibitor is an aryloxyalkyl-substituted oxirane carboxylic acid of the following formula I wherein Ar is a substituted phenyl radical R1 is a hydrogen atom; R2 is a hydrogen atom, a halogen atom, or a 1-4 C lower alkyl group; a 1-4 C lower alkoxy group, a nitro group, a trifluoromethyl group, a fully or predominantly fluorine-substituted 1-3 C alkoxy group or R3 is a hydrogen atom or a 1-4 C lower alkyl group; R5 is a 1-4 C lower alkyl group; Y is the grouping —O—; z is 0 s is 1 or 2 r is 2-s n and m are integer >0 with 2<n+m<8, and as well as pharmaceutically acceptable salts or derivatives of said aryloxyalkyl-substituted oxirane carboxylic acid.